Get the Stockscreener App
247.73
0.62%
1.60
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $247.73, with a volume of 2.46M.
It is up +0.62% in the last 24 hours and up +5.72% over the past month.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$246.13
Open:
$245.58
24h Volume:
2.46M
Relative Volume:
1.96
Market Cap:
$47.73B
Revenue:
$293.96B
Net Income/Loss:
$1.51B
P/E Ratio:
32.99
EPS:
7.51
Net Cash Flow:
$3.00B
1W Performance:
-2.58%
1M Performance:
+5.72%
6M Performance:
+2.72%
1Y Performance:
+4.20%
1-Day Range:
$244.75
$248.81
1-Week Range:
$244.75
$262.25
52-Week Range:
$214.77
$262.25
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
247.66 | 47.73B | 293.96B | 1.51B | 3.00B | 7.51 |
|
MCK
Mckesson Corporation
|
598.34 | 77.79B | 330.19B | 2.54B | 4.31B | 19.31 |
|
CAH
Cardinal Health Inc
|
127.32 | 30.95B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
78.76 | 9.32B | 12.50B | 314.00M | 421.00M | 2.44 |
|
PDCO
Patterson Companies Inc
|
31.02 | 2.72B | 6.55B | 155.22M | -823.13M | 1.71 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora (NYSE:COR) Price Target Raised to $280.00 at Evercore ISI - MarketBeat
Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move - Benzinga
Ledyard National Bank Purchases 3,058 Shares of Cencora, Inc. (NYSE:COR) - MarketBeat
CORCencora, Inc. Latest Stock News & Market Updates - StockTitan
Walgreens sells more shares in Cencora; cuts stake to 6% - MSN
To Pay Down Debt, Walgreens Sells More Cencora Shares For $300 Million - Forbes
Walgreens Boots Alliance Says Co Settles Certain Prepaid Variable Share Forward Transactions, Sells Related Shares Of Cencora For Approx $300 Mln Of Proceeds - Marketscreener.com
Fortune 500 Giant Cencora's Strategic $50M Stock Repurchase Signals Major Shift - StockTitan
Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds - Walgreens Boots Alliance Investor Relations
Stock Yards Bank & Trust Co. Makes New $290,000 Investment in Cencora, Inc. (NYSE:COR) - MarketBeat
Cencora Earnings Call: Strong Start Amid Challenges - TipRanks
Cencora, Inc. (NYSE:COR) Shares Sold by abrdn plc - MarketBeat
Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program - BioSpace
Cencora (NYSE:COR) Sets New 1-Year High on Strong Earnings - MarketBeat
Meritage Portfolio Management Sells 1,162 Shares of Cencora, Inc. (NYSE:COR) - MarketBeat
Deutsche Bank Adjusts Cencora Price Target to $264 From $260, Maintains Buy Rating - Marketscreener.com
Cencora First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Leerink raises Cencora stock price target to $301, maintains Outperform By Investing.com - Investing.com South Africa
Cencora Inc (COR) Q1 2025 Earnings Call Highlights: Strong Reven - GuruFocus.com
Cencora Inc (COR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Decoding Cencora Inc (COR): A Strategic SWOT Insight - GuruFocus.com
Cencora, Inc. (NYSE:COR) Plans Quarterly Dividend of $0.55 - MarketBeat
Cencora Reports Strong Start to Fiscal 2025 - TipRanks
Here's What Key Metrics Tell Us About Cencora (COR) Q1 Earnings - MSN
Cencora: Fiscal Q1 Earnings Snapshot - Huron Daily Tribune
Leerink raises Cencora stock price target to $301, maintains Outperform - Investing.com India
Cencora Inc earnings beat by $0.24, revenue topped estimates - Investing.com
Cencora Q1 Earnings: Revenue And EPS Beat On Strong Push From Obesity Drugs, Specialty Medicines - Benzinga
Cencora shares edge up as results beats expectations, raises outlook - MSN
Cencora raises 2025 profit forecast on specialty drug demand - MSN
Cencora Raises 2025 Profit Forecast On Specialty Medicine Demand - Finimize
Cencora, Inc. (NYSE:COR) Shares Sold by Martin Capital Partners LLC - MarketBeat
Cencora Inc Surpasses Q1 FY2025 Revenue Estimates with $81.5 Bil - GuruFocus.com
Cencora Reports Fiscal 2025 First Quarter Results -February 05, 2025 at 07:48 am EST - Marketscreener.com
Cencora Reports Strong Q1 2025 Financial Performance - TipRanks
Cencora shares edge up as results beats expectations, raises outlook By Investing.com - Investing.com UK
Cencora Delivers Blockbuster Q1: $81.5B Revenue Crushes Expectations, EPS Guidance Boosted - StockTitan
Cencora (NYSE:COR) Stock Quotes, Forecast and News Summary - Benzinga
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Deutsche Bank Adjusts Price Target on Cencora to $260 From $252 -February 04, 2025 at 09:27 am EST - Marketscreener.com
Cencora raises 2025 profit forecast on specialty drug demand -February 05, 2025 at 07:19 am EST - Marketscreener.com
U.S. Capital Wealth Advisors LLC Buys 1,101 Shares of Cencora, Inc. (NYSE:COR) - MarketBeat
Exchange Traded Concepts LLC Cuts Holdings in Cencora, Inc. (NYSE:COR) - MarketBeat
Cencora to Report Q1 Earnings: Is a Beat Likely for the Stock? - MSN
Why Cencora (COR) is a Top Value Stock for the Long-Term - Yahoo Finance
Stay Ahead of the Game With Cencora (COR) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Oregon Pacific Wealth Management LLC Invests $281,000 in Cencora, Inc. (NYSE:COR) - MarketBeat
Spire Wealth Management Acquires 4,022 Shares of Cencora, Inc. (NYSE:COR) - MarketBeat
The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health - Yahoo Finance Australia
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):